One recovery stock I’d consider buying today, and one I’d ignore

Harvey Jones loves a good turnaround play and there’s one here that tickles his fancy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Smiths Group (LSE: SMIN) is up almost 6% today on news that it plans to separate its underperforming medical division from its much stronger core industrial tech business. This is the news many investors had been waiting for.

The Smiths

Management said that breaking off Smiths Medical should allow the remainder of the group “to concentrate on growing as an Industrial Technology group, united by shared business characteristics and a common operating model.”

This should have the further benefit of freeing Smiths Medical to deliver on its full potential and capitalise “on its leading positions, large programme of new product launches and to exploit value creating opportunities in its rapidly changing market,” although investors will have to wait until its interim results in March to hear more.

Stretch out and wait

The group also published a first quarter trading update today that reported expectations for the year remain unchanged.

Investors in Smiths need something to feel less miserable about, with the stock down 22% over the past six months and trading 5% lower than five years ago. The medical devices and equipment division has done particularly poorly, having been hit by regulatory and contract challenges (now abating), but previous attempts to offload it floundered. At least it remains on course to grow in the second half.

Well I wonder

Its John Crane arm continues to show “good growth” with an acceleration in orders and further strong aftermarket demand. Smiths Detection expects a strong second half, supported by a robust order book, while Smiths Interconnect and Flex-Tek are growing well.

Investors are banking on the fact that the break-up of the £5.5bn FTSE 100 business will unlock value. Earnings growth has been patchy for years, while revenues have grown only slowly. Despite recent woes, there’s no discount with the stock trading at 14.9 times earnings, with a forecast yield of 3.3%, and cover of 2.1. One for your watch list, though.

Boeing, Boeing, gone

Aerospace and defence group Cobham (LSE: COB) is down around 2% today after publishing a trading statement for its first 10 months that was as expected, while it “continues to make progress in executing its turnaround programme.”

Underlying operating profit in Mission Systems and Communications and Connectivity was stronger, offsetting weaker performances in Advanced Electronic Solutions and Aviation Services.

The FTSE 250-listed group’s biggest headache is its KC-46 aerial refuelling tanker programme for Boeing. The US aviation giant is claiming as yet unquantified damages from Cobham, and is withholding payments of its invoices.

Damaging

Today, Cobham said it has delivered a total of 18 production-standard Centerline Drogue Systems under its KC-46 programme, adding that “qualification of the Wing Aerial Refuelling Pods remains in its early stages with risks relating to schedule and cost.” Discussions with Boeing continue regarding its “unquantified damages assertions and payment withhold,” so there’s no clarity for investors here, which hasn’t helped the share price.

Management anticipates “significant trading activity” in the final two months, but it’s hard to construct a buy case with the stock trading at a pricey 21.6 times forecast earnings (despite falling 48% in three years), and yielding just 0.6%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

harveyj has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

These FTSE 100 stocks are making a joke of the S&P 500 — but I’m eyeing more ‘rational’ options

Many FTSE 100 stocks are soaring ahead of their S&P 500 rivals in 2025 but Mark Hartley’s looking for some…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

The Nvidia share price hit an all-time high this week. But could it still be a bargain?

The Nvidia share price has soared 1,466% in just five years. This writer reckons the best may yet be to…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

How much does someone need to invest to target a second income of £15k – or £150k?

A second income from dividend shares? It's a well-worn path -- and this writer sees some attractions to the approach.…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could the stock market crash in the second half of 2025?

As the FTSE 100 hits a new high, could a stock market crash be coming? Our writer thinks there's a…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Start investing this summer with a spare £250? Here’s how!

Christopher Ruane explains how an investor with a few hundred pounds to spare and no prior experience could look to…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Is Palantir stock the new Nvidia? Why UK investors should (or shouldn’t) care

Palantir stock’s the top performer on the S&P 500 this year. Should UK investors consider it amid a blistering AI-fuelled…

Read more »

Investing Articles

3 FTSE 100 shares I think look undervalued

The FTSE 100 may be hitting record highs but there are still bargains to be had on the index. I…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

£20,000 in savings? Here’s how to target £841 of passive income each month

Passive income plans don't need to be complicated. Our writer explains how someone could target a sizeable second income buying…

Read more »